



Please Direct All Correspondence to Customer Number **30,313**

**TRANSMITTAL LETTER**  
**INFORMATION DISCLOSURE STATEMENT**

Applicant : Eaton, et al.  
App. No : 10/063,561  
Filed : May 2, 2002  
For : SECRETED AND TRANSMEMBRANE  
POLYPEPTIDES AND NUCLEIC ACIDS  
ENCODING THE SAME  
Examiner : Patricia Ann Duffy  
Art Unit : 1645

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

April 12, 2005

(Date)

Daniel Hart, Reg. No. 40,637

**Mail Stop Amendment**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement and PTO/SB/08 equivalent listing references for consideration:
  - (X) Listing forty-three (43) references.
  - (X) Enclosing twenty-five (25) references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

Daniel Hart

Registration No. 40,637

Attorney of Record

Customer No. 30,313

(619) 235-8550

## INFORMATION DISCLOSURE STATEMENT

Applicant : Eaton, et al.  
App. No : 10/063,561  
Filed : May 2, 2002  
For : SECRETED AND  
TRANSMEMBRANE POLYPEPTIDES  
AND NUCLEIC ACIDS ENCODING  
THE SAME  
Examiner : Patricia Ann Duffy  
Art Unit : 1645

## CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

April 12, 2005

(Date)

*Daniel Hart*

Daniel Hart, Reg. No. 40,637

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is an Information Disclosure Statement by Applicant (PTO/SB/08 equivalent) listing forty-three (43) references to be considered by the Examiner. Also enclosed are twenty-five (25) foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required. If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: April 12, 2005

By: *Daniel Hart*

Daniel Hart

Registration No. 40,637

Attorney of Record

Customer No. 30,313

(619) 235-8550

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Multiple sheets used when necessary)

SHEET 1 OF 3

Application No.	10/063,561
Filing Date	May 2, 2002
First Named Inventor	Eaton, et al.
Art Unit	1645
Examiner	Patricia Ann Duffy
Attorney Docket No.	GNE.3230R1C41

## U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	5,536,637	07-16-1996	Jacobs	
	2	6,025,156	02-15-2000	Gwynn, et al.	
	3	6,124,433	09-26-2000	Falb, et al.	
	4	6,156,500	12-05-2000	Falb, D.	
	5	6,162,604	12-19-2000	Jacob	
	6	6,204,371 B1	03-20-2001	Levinson	
	7	6,228,582 B1	05-08-2001	Rodier, et al.	
	8	6,395,306 B1	05-28-2002	Cui, et al.	
	9	6,414,117 B1	07-02-2002	Levinson	
	10	6,465,185 B1	10-15-2002	Goldfine, et al.	
	11	6,498,235 B2	12-24-2002	Sheppard, et al.	
	12	6,534,641 B2	03-18-2003	Falb, et al.	
	13	6,562,343 B1	05-13-2003	Levinson, D. A.	
	14	6,645,499 B1	11-11-2003	Lal, et al.	
	15	6,730,502 B2	05-04-2004	Van Hijum, et al.	
	16	6,737,522 B2	05-18-2004	Sundick, et al.	
	17	2002/0119130 A1	08-29-2002	Eaton, et al.	
	18	2003/0027275 A1	02-06-2003	Baker, et al.	

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>
	19	WO 00/77037 A2	12-21-2000	Genentech, Inc.		
	20	WO 00/77037 A3	12-21-2000	Genentech, Inc.		
	21	WO 01/68848 A2	09-20-2001	Genentech, Inc.		

Examiner Signature

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Application No.	10/063,561
	Filing Date	May 2, 2002
	First Named Inventor	Eaton, et al.
	Art Unit	1645
(Multiple sheets used when necessary)	Examiner	Patricia Ann Duffy
SHEET 2 OF 3	Attorney Docket No.	GNE.3230R1C41

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	22	ALBERTS, et al. 1994. <i>Molecular Biology of the Cell, 3rd Edition</i> , pp. 403-404, 453. New York: Garland Publishing.	
	23	ALBERTS, et al. 2002. <i>Molecular Biology of the Cell 4th Edition</i> , pp. 302, 363-364, 379, 435. New York: Garland Publishing.	
	24	GÖKMAN-POLAR, et al. 2001. Elevated protein kinase C $\beta$ II is an early promotive event in colon carcinogenesis. <i>Cancer Research</i> , 61:1375-1381.	
	25	GRIMALDI, et al. 1989. The t(5;14) chromosomal translocation in a case of acute lymphocytic leukemia joins the interleukin-3 gene to the immunoglobulin heavy chain gene. <i>Blood</i> , 73(8):2081-2085.	
	26	GYGI, et al. 1999. Correlation between protein and mRNA abundance in yeast. <i>Molecular and Cellular Biology</i> , 19(3):1720-1730.	
	27	HANNA, et al. Aug. 1999. HER-2/neu breast cancer predictive testing. <i>Pathology Associates Medical Laboratories</i> .	
	28	HAYNES, et al. 1998. Proteome analysis: Biological assay or data archive? <i>Electrophoresis</i> , 19:1862-1871.	
	29	HU, et al. 2003. Analysis of genomic and proteomic data using advanced literature mining. <i>Journal of Proteome Research</i> , 2:405-412.	
	30	HYMAN, et al. 2002. Impact of DNA amplification on gene expression patterns in breast cancer. <i>Cancer Research</i> , 62:6240-6245.	
	31	KONOPKA, et al. 1986. Variable expression of the translocated c-abl oncogene in Philadelphia-chromosome-positive B-lymphoid cell lines from chronic myelogenous leukemia patients. <i>Proc. Natl. Acad. Sci. USA</i> , 83:4049-4052.	
	32	LEWIN, B. 1994. Oncogenes: Gene expression and cancer, Chap. 39, pp. 1196-1201. <i>Genes V</i> . New York: Oxford University Press.	
	33	LEWIN, B. 1997. Regulation of Transcription, Chap. 29, pp. 847-848. <i>Genes VI</i> . New York: Oxford University Press.	
	34	MEEKER, et al. 1990. Activation of the interleukin-3 gene by chromosome translocation in acute lymphocytic leukemia with eosinophilia. <i>Blood</i> , 76(2):285-289.	
	35	MERIC, et al. 2002. Translation initiation in cancer: A novel target for therapy. <i>Molecular Cancer Therapeutics</i> , 1:971-979.	
	36	ØRNTØFT, et al. 2002. Genome-wide study of gene copy numbers, transcripts, and protein levels in pairs of non-invasive and invasive human transitional cell carcinomas. <i>Molecular &amp; Cellular Proteomics</i> , 1:37-45.	
	37	PENNICA, et al. 1998. WISP genes are members of the connective tissue growth factor family that are up-regulated in Wnt-1-transformed cells and aberrantly expressed in human colon tumors. <i>Proc. Natl. Acad. Sci. USA</i> , 95:14717-14722.	
	38	POLLACK, et al. 2002. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. <i>PNAS</i> , 99(20):12963-12968.	
	39	SINGLETON, et al. 1992. Clinical and pathologic significance of the c-erbB-2 (HER-2/neu) oncogene. <i>Pathol. Annu.</i> , 1(27):165-190.	

Examiner Signature	Date Considered
<b>*Examiner:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

[illegible]

Examiner Signature	Date Considered
<p><b>*Examiner:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

**T<sup>1</sup>** - Place a check mark in this area when an English language Translation is attached.